A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).

导出 LinkOut

翻译打印收藏纠错

作者： Ticiana A,Leal ^[1] ; Marina N,Sharifi ^[2] ; Nancy,Chan ^[3] ; Robert,Wesolowski ^[4] ; Anita A,Turk ^[5] ; Justine Y,Bruce ^[2] ; Ruth M,O'Regan ^[6] ; Jens,Eickhoff ^[7] ; Lisa M,Barroilhet ^[8] ; Jyoti,Malhotra ^[3] ; Janice,Mehnert ^[9] ; Eugenia,Girda ^[3] ; Elizabeth,Wiley ^[4] ; Natalie,Schmitz ^[10] ; Shannon,Andrews ^[2] ; Glenn,Liu ^[2] ; Kari B,Wisinski ^[2]

作者单位： Winship Cancer Institute, Emory University, Georgia. ^[1] University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA. ^[2] Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. ^[3] Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA. ^[4] Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA. ^[5] Department of Medicine, University of Rochester, Rochester, New York, USA. ^[6] Department of Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. ^[7] Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. ^[8] Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, New York City, USA. ^[9] School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA. ^[10]

关键词 BMN673 PARP carboplatin paclitaxel talazoparib

主题词人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);卡铂(Carboplatin);肿瘤(Neoplasms);紫杉酚(Paclitaxel);聚ADP核糖聚合酶类(Poly(ADP-ribose) Polymerases)

DOI 10.1002/cam4.4724

PMID 35396812

发布时间 2023-07-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer medicine

2022年11卷21期

3969-3981页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).

Cancer medicine

相似文献

Cancer medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).

Cancer medicine

相似文献

Cancer medicine

相关期刊

检索历史清除